[Antibodies against citrullinated peptides in clinical practice and research].

Association of levels of antibodies against citrullinated cyclic peptides and citrullinated α-enolase in chronic and aggressive periodontitis as a risk factor of Rheumatoid arthritis: a case control study. J Transl Med (2015) 0.79

Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum (2004) 7.79

Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest (1998) 6.92

Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol (2003) 4.64

The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol (1999) 3.22

Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol (2008) 3.14

Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum (2007) 2.40

Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis (2008) 2.27

Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Biol (2006) 2.05

Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum (2007) 1.93

Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum (2008) 1.68

Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis (2007) 1.65

Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum (2005) 1.55

Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum (2008) 1.48

Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol (2008) 1.42

Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination. Arthritis Res Ther (2008) 1.40

Treatment of rheumatoid arthritis. BMJ (2006) 1.30

Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther (2008) 1.11

A tale of two citrullines--structural and functional aspects of myelin basic protein deimination in health and disease. Neurochem Res (2006) 1.02

IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA. Rheumatology (Oxford) (2008) 0.98

Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope. Clin Exp Rheumatol (2008) 0.95

Rheumatoid factor on a daily basis. Autoimmunity (2005) 0.92

Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets? Clin Rev Allergy Immunol (2008) 0.88

The relationship between anti-cyclic citrullinated peptide and bone mineral density and radiographic damage in patients with rheumatoid arthritis. Scand J Rheumatol (2008) 0.86

Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis. Ann Rheum Dis (2008) 0.81

What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies? J Rheumatol (2008) 0.79

[Autoantibody profile in rheumatoid arthritis]. Z Rheumatol (2007) 0.79

The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders. J Rheumatol (2009) 0.77

Adenoviral transduction supports matrix expression of alginate cultured articular chondrocytes. Biotechnol Bioeng (2012) 0.76

Autoantibody-mediated agranulocytosis in association with chronic GVHD. Bone Marrow Transplant (2008) 0.75